Brown Rudnick acted on behalf of the company (Midatech Pharma plc), who announced on 28 September 2017 that they intend to raise £6m by way of a Placing and an additional £2m by way of an Open Offer.  It is expected that the Placing Shares and Open Offer Shares will be admitted to trading on AIM on 17 October 2017.   

Midatech is an international specialty pharmaceutical company focused on the research and development of a pipeline of medicines for oncology and related therapeutic areas.

The Brown Rudnick team was led by London Corporate partner Tim Matthews and Associate Tom Braiden

To learn more about this deal please read the following press release: